Tests of blood coagulation and hemostasis. I. The prothrombin time

JAMA ◽  
1966 ◽  
Vol 196 (1) ◽  
pp. 33-34 ◽  
Author(s):  
P. Didisheim
Keyword(s):  
Prothrombin Time ◽  
Blood Coagulation

Antihemostatic Effect of Hsien-Ho-T'sao (Agrimonia pilosa)

1984 ◽  
Vol 12 (01n04) ◽  
pp. 116-123 ◽  
Author(s):  
Jih-Pyang Wang ◽  
Mei-Feng Hsu ◽  
Che-Ming Teng
Keyword(s):  
Prothrombin Time ◽  
Blood Coagulation ◽  
Partial Thromboplastin Time ◽  
Bleeding Time ◽  
Fibrinogen Level ◽  
Platelet Rich Plasma ◽  
Water Extract ◽  
Activated Partial Thromboplastin Time ◽  
Thrombin Time

Bleeding time in rats was markedly prolonged after the adminstration of the water extract of Hsien-Ho-T'sao. This antihemostatic effect was more marked in the group of i.p. injection of the drug than in the group of p.o. administration for 2 to 7 consecutive days. Blood coagulation studies showed that plasma prothrombin time, activated partial thromboplastin time and stypven time were prolonged, while thrombin time adnd fibrinogen level were not changed. The thromboelastographic recording showed that reation time was prolonged and maximal elasticity of clot was decreased. In addition, ADP- and collagen- induced aggregations of platelet-rich plasma was suppressed. In conclusion, the prolongation of the bleeding time might be due to both anticoagulant and antiplatelet action of the drug.

Chicken prothrombin, thrombin, and fibrinogen

1961 ◽  
Vol 200 (5) ◽  
pp. 1013-1017 ◽  
Author(s):  
C. H. Bigland ◽  
D. C. Triantaphyllopoulos
Keyword(s):  
Prothrombin Time ◽  
Blood Coagulation ◽  
Thrombin Time ◽  
Bovine Thrombin ◽  
Chicken Brain ◽  
One Stage ◽  
Highly Sensitive ◽  
Avian Blood ◽  
The Mean ◽  
The One

Avian blood coagulation studies revealed the mean one-stage prothrombin time of plasma from 100 chickens, 10 weeks of age, as determined with chicken brain thromboplastin, to be 11.4 seconds, compared with 10–300 seconds found by other workers; the mean prothrombin content was 137% of human prothrombin levels, as determined by the one-stage prothrombin-time technique, but only 53% by the adsorption and elution technique used. Fibrinogen determinations on the same plasma revealed a mean of 346 mg/ 100 ml of plasma, compared with 250–400 for humans. Chicken thrombin was prepared which gave a mean thrombin time on the same, but buffered, plasma of 12 seconds. Coagulation of chicken plasma with chicken thrombin was found to be highly sensitive to variations in pH, being 12 seconds at pH 7.1, but lengthening to over 60 seconds at pH 7.7. Greatly increased clotting times of chicken plasma with bovine thrombin and with rabbit thromboplastin indicated evidence of species specificity.

THE BLOOD COAGULATION MECHANISM OF FROGS, WITH RESPECT TO THE SPECIES SPECIFICITY OF THROMBO PLASTIN, TO INTRACARDIAL THROMBIN INJECTION, AND TO THE EFFECT OF SEASONAL CHANGES

1952 ◽  
Vol 30 (5) ◽  
pp. 420-424
Author(s):  
John J. Spitzer ◽  
Judy A. Spitzer
Keyword(s):  
Prothrombin Time ◽  
Blood Coagulation ◽  
Seasonal Changes ◽  
Thrombin Injection ◽  
Clotting Time ◽  
Coagulation Time ◽  
Coagulation Mechanism ◽  
Significant Difference ◽  
Whole Blood Coagulation Time ◽  
Blood Coagulation Mechanism

1. The prothrombin time of frogs is much shorter using frog rather than rabbit thromboplastin in the determination. The contrary is true for dogs, rabbits, and rats. In guinea pigs there was no significant difference between the two kinds of thromboplastin. 2. The intracardiai injection of thrombin in frogs induces a triphasic response regarding the whole blood coagulation time: (a) shortening, (b) prolongation, and (c) return towards the normal. The return is quicker than in the case of mammals. 3. The following seasonal changes were obtained in “winter” frogs as compared to “summer” animals: (a) pro longed clotting time, (b) increased prothrombin time, and (c) lessened effectiveness of intracardiai thrombin solution. The clotting time with added thrombin was not changed.

Mathematical Model for the Blood Coagulation Prothrombin Time Test

1998 ◽  
Vol 89 (5) ◽  
pp. 227-232 ◽  
Author(s):  
Mikhail A Khanin ◽  
Dmitrii V Rakov ◽  
Alexander E Kogan
Keyword(s):  
Mathematical Model ◽  
Prothrombin Time ◽  
Blood Coagulation ◽  
Time Test

The blood coagulation system of rats under the influence of laser radiation in different time parameters

2019 ◽  
Vol 11 (1) ◽  
pp. 19-26
Author(s):  
Oksana Ketsa ◽  
Mykhailo Marchenko ◽  
Nadiia Bodnarjuk
Keyword(s):  
Prothrombin Time ◽  
Laser Irradiation ◽  
Blood Coagulation ◽  
Laser Diode ◽  
Coagulation System ◽  
Simultaneous Increase ◽  
Thrombin Time ◽  
Blood Coagulation System ◽  
Group I ◽  
Time Parameters

The influence of different terms of laser irradiation on vascular-platelet and coagulation units of blood coagulation system is investigated. The rats were irradiated with a laser diode in the red spectrum (650 nm) with a power of 50 mW. Rats were divided into two groups: group I - rats, which were irradiated daily for 2 minutes; group II - rats, which were irradiated daily for 4 minutes. Euthanasia of animals was performed on the 7th and 14th days after the onset of irradiation. For the study of the blood coagulation system of rats used biochemical coagulogram with the analysis of the following indicators - the content of fibrinogen, thrombin and prothrombin time, activated partial thromboplastin time (APTT), platelet count. The content of lymphocytes and erythrocyte sedimentation rate were determined also. In the work used blood plasma with sodium citrate. It has been found that daily four-minute laser irradiation in the abdominal area for two weeks leads to a decrease in the concentration of factor I blood clotting (fibrinogen) and an increase in thrombin time. At the same time, prolongation of prothrombin time and APTT was detected, indicating a deficiency of other factors of blood coagulation - II, V, VII-XII, and the presence of anticoagulant status, which may be associated with inhibition of the internal pathway of clotting. Thrombocytopenia is probably caused by the increased destruction of platelets or their insufficient formation as a result of dysfunction of hematopoietic organs. The two-minute effect of laser irradiation does not affect the clinical and biochemical parameters of the blood coagulation system of rats after a weekly daily action of the laser diode. Two weeks irradiation is accompanied by processes of hypocoagulation, as evidenced by a decrease in fibrinogen levels, platelet counts, and a simultaneous increase in APTT, thrombin and prothrombin time.

scholarly journals Evolution of blood coagulation activators and inhibitors in the healthy human fetus

Blood ◽  
1996 ◽  
Vol 88 (3) ◽  
pp. 900-906 ◽  
Author(s):  
P Reverdiau-Moalic ◽  
B Delahousse ◽  
G Body ◽  
P Bardos ◽  
J Leroy ◽  
...  
Keyword(s):  
Prothrombin Time ◽  
Blood Coagulation ◽  
Protein S ◽  
Screening Tests ◽  
Factor V ◽  
Heparin Cofactor Ii ◽  
Healthy Human ◽  
Intrauterine Life ◽  
Coagulation Proteins ◽  
Low Levels

Blood coagulation proteins were determined in 285 healthy fetuses from 19 to 38 weeks' gestation and compared with those of 60 normal full- term newborns and 40 adult controls. Prolongation of the coagulation screening tests, prothrombin time, activated partial prothrombin time, and thrombin clotting time, in fetuses throughout intrauterine life was explained by low levels of vitamin K-dependent factors (II, VII, IX, and X), contact factors (XI, XII, prekallikrein, and high-molecular- weight kininogen), factor V, factor VIII, and fibrinogen. Low levels of antithrombin III, heparin cofactor II, protein C and protein S, and tissue factor pathway inhibitor were also found, and these probably contributed to a satisfactory hemostatic balance. Some of these parameters were evaluated by both immunologic and functional assays to detect possible “fetal” proteins. An increase in factor levels was observed after the thirty-fourth week of intrauterine life for most of the coagulation activators and inhibitors, but only factors V and VIII reached adult values at birth. This study therefore showed that fetal hemostasis is a dynamic system that evolves gradually toward the neonatal state and then toward the adult state.

scholarly journals Research of hemostasis in experimental antiphospholipid syndrome

2015 ◽  
Vol 17 (3) ◽  
Author(s):  
О. Z. Yaremchuk
Keyword(s):  
Prothrombin Time ◽  
Blood Coagulation ◽  
Antiphospholipid Syndrome ◽  
International Normalized Ratio ◽  
Coagulation System ◽  
Study Group ◽  
Time Increase ◽  
Female Mice ◽  
Blood Coagulation System

<p>This study investigated changes of indicators in blood coagulation system and platelet levels in experimental<br />antiphospholipid syndrome (APS), which was modeled in female mice of the line BALB/c. The results show that the<br />study group of the animals with APS reduced number of platelets, reduced prothrombin time, increase of prothrombin<br />index and decrease of international normalized ratio.</p>

scholarly journals DIAGNOSTIC ROLE OF SYSTEMIC INFLAMMATION, BLOOD COAGULATION AND PADUA PREDICTION SCORE IN LUNG THROMBOSIS RISK ESTIMATION IN HOSPITALIZED PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA

2019 ◽  
Vol 72 (2) ◽  
pp. 149-153
Author(s):  
Tetyana Pertseva ◽  
Tetyana Kireieieva ◽  
Mariia Krykhtina ◽  
Kseniia Bielosludtseva ◽  
Kateryna Dyagovets
Keyword(s):  
Prothrombin Time ◽  
Blood Coagulation ◽  
Systemic Inflammation ◽  
Main Group ◽  
Hospitalized Patients ◽  
Control Group ◽  
The Mean ◽  
Old Men ◽  
D Dimer

Introduction: Some coagulation and thrombotic disorders during severe CAP could lead to some intravascular disorders and even be the reason of lethal end in hospitalized patients with CAP. But this fact hadn’t been established to the end yet. The aim was to study the intravascular changes in patients with severe CAP and to estimate the role of parameters of systemic inflammation (procalcitonin (PCT), C-reactive protein (CRP)), blood coagulation test (fibrinogen, D-dimer, heparin time, prothrombin time) and risk of thrombosis in patients with moderate and severe CAP. Materials and methods: The main group was 63 patients with moderate to severe CAP. The mean age was 54.0 [37.0–63.0] years old, men – 46 (73.0%)). Depending on the severity all patients of the main group were divided into 2 subgroups: subgroup 1 – 36 patients with moderate CAP (the mean age was 51.0 [32.5–62.5] years old, men – 29 (80.5%)), subgroup 2 – 27 patients with severe CAP (the mean age was 56.0 [46.0–68.0] years old, men – 17 (63.0%). Subgroups had no significant difference according to age (p=0,348) and sex (p=0,237). Received results were compared with values in control group. The control group was 10 healthy people (the mean age was 52.0 [35.6–62.0] years old, men – 5 (50.0%)). Results and conclusions: Patients with severe CAP had significantly higher levels of PCT, CRP, D-dimer, prothrombin time, heparin index and the lowest level of heparin time. This fact shows the highest risk of thrombosis in patients with severe CAP on the background of severe systemic inflammation. The mean level of scores by Padua scale in patients with severe CAP was 5.0 [5.0–6.0] scores, which was significantly higher than in patients with moderate CAP, who had 1.0 [1.0–2.0] scores. On autopsy of 5 died patients with severe CAP we found thrombosis of lung vessels which differ from embolism or post-mortem blood clots. These changes maybe reflect systemic thrombosis at patients with severe CAP and could be the reasons of increased mortality in this category of patients.

scholarly journals Effects of Exenatide on Blood Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes

2021 ◽  
Author(s):  
Yaqin Zhang ◽  
Ruofei Chen ◽  
Yangyang Jia ◽  
Zongwen Shuai ◽  
Mingwei Chen
Keyword(s):  
Type 2 Diabetes ◽  
Platelet Count ◽  
Platelet Aggregation ◽  
Prothrombin Time ◽  
Blood Coagulation ◽  
Density Lipoprotein ◽  
Normal Control Group ◽  
Control Group ◽  
Case Group

Abstract Background: To explore the effect of glucagon-like peptide-1 receptor (GLP-1R) agonist exenatide on blood coagulation function and platelet aggregation function in patients with type 2 diabetes mellitus (T2DM).Method: Thirty patients with newly diagnosed T2DM were enrolled as the case group, and 30 healthy people with matching age and sex were selected as the control group. Patients in the case group received exenatide treatment for 8 weeks. Collect the general clinical data and biochemical indicators of the patients in the case group before and after 8 weeks of exenatide treatment and the control subjects, and detect their peripheral blood platelet count (×1012 g/L), plasma prothrombin time (PT, s), prothrombin time activity (PTA, %), activated partial thromboplastin time (APTT, s), international normalized ratio (INR), fibrinogen (FIB, g/L), plasma thrombin time (TT, s) , Fibrin degradation products (FDP, μg/mL), D-dimer (DD, μg/mL), nitric oxide (NO, μmol/L), CD62p (%), platelet activation complex-1 (PAC-1, %) and platelet aggregation induced by collagen, epinephrine, arachidonic acid (AA, %), and adenosine diphosphate (ADP, %).Results: There was no significant difference in platelet count, PLT, PT, PTA, APTT, TT, INR, FDP, DD between the case group and the control group; the FIB, CD62p, PAC-1, platelet aggregation rates of the case group (EPI 87.23±6.84 , ADP 87.51±9.21, AA 90.17±3.19) is higher than normal control group (EPI 82.15±5.37, ADP 82.38±6.42, AA 83.41±6.17, P＜0.05), NO level is lower than normal control group (68.1±14.7 vs. 79.4±11.2, P<0.05); After 8 weeks of exenatide treatment in the case group, CD62p, PAC-1, and platelet aggregation rates were lower than before (EPI: 81.62±9.02 vs. 87.23±6.84, AA: 84.62±7.12 vs. 90.17±3.19, P＜0.05), the level of NO was higher than before (89.6±15.8 vs. 68.1±14.7); Pearson correlation analysis showed that the changes in platelet aggregation rates (Δ EPI, ΔAA) of patients in the case group after 8 weeks of exenatide treatment were positively correlated with the changes in body mass index (BMI, kg/m2), waist circumference (cm), weight (kg), total cholesterol (TCH, mmol/L), triglycerides (TG, mmol/L), low-density lipoprotein (LDL-C, mmol/L), fasting plasma glucose (FPG, mmol/L), Hemoglobin A1c (HbA1c, %), CD62p, PAC-1 (P<0.05), and negatively correlated with the change of high density lipoprotein (HDL-C, mmol/L) and NO (P<0.05). Multiple linear regression analysis showed that the changes of NO, CD62p and PAC-1 were independent risk factors affecting the changes of platelet aggregation rates.Conclusions: The GLP-1R agonist exenatide can inhibit the activation state of platelets in patients with T2DM, reduce the platelet aggregation rate, and inhibit thrombosis, which is beneficial to reduce the risk of cardiovascular events.

Sign in / Sign up

Export Citation Format

Share Document